97914-53-9

Upstream product

• 67-56-1 methanol 
• 97914-59-5 2-(difluoromethoxy)benzoic acid 

Downstream Products

• 1608129-78-7 C₁₉H₂₁F₂N₃O₅ 
• 1040724-27-3 5-(2-difluoromethoxyphenyl)-2H-pyrazol-3-ylamine 
• 1040721-25-2 N-[5-(2-difluoromethoxyphenyl)-2H-pyrazol-3-yl]-4-pyrrolidin-1-yl-butyramide formate salt 
• 1040721-31-0 N-[5-(2-difluoromethoxyphenyl)-2H-pyrazol-3-yl]-4-piperidin-1-yl-butyramide formate salt 
• 1608129-59-4 3-piperidin-1-yl-pyrrolidine-1-carboxylic acid [5-(2-difluoromethoxyphenyl)-2H-pyrazol-3-yl]amide 
• 1608129-74-3 5-amino-3-(2-difluoromethoxyphenyl)pyrazole-1-carboxylic acid tert-butyl ester 
• 1016690-71-3 C₁₀H₇F₂NO₂ 

Relevant academic research and scientific papers

SYNTHESIS OF DIFLUOROMETHYL ETHERS AND SULFIDES

The synthesis of difluoromethyl ethers and sulfides with a simple, non-ozone- depleting reagent is described. The difluoromethylation of phenols with this reagent occurs at room temperature within minutes with exceptional functional group tolerance. The mild conditions makes possible tandem processes for the conversion of aryl boronic acids, aryl halides and arenes to difluoromethyl ethers. Mechanistic studies support a reaction pathway involving nucleophilic attack of the phenolate to difluorocarbene.

Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor

α7 nicotinic acetylcholine receptor agonists are promising therapeutic candidates for the treatment of cognitive impairment. As a follow up of our internal medicinal chemistry program we investigated a novel series of α7 nAChR agonists. Starting from molecular docking studies on two series of molecules recently developed in our laboratories, an alternative scaffold was designed attempting to combine the optimal features of these previously identified urea and pyrazole compounds. Based on our previous SAR knowledge and on predicted drug-like properties, a small library was synthesized in parallel manner, affording compounds with excellent α7 nAChR activity, selectivity and preliminary ADME profile.

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.